Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy
- Author(s)
- He, MY; Halford, MM; Liu, R; Roy, JP; Grant, ZL; Coultas, L; Thio, N; Gilan, O; Chan, YC; Dawson, MA; Achen, MG; Stacker, SA;
- Details
- Publication Year 2021-07-15,Volume 4,Issue #1,Page 878
- Journal Title
- Communications Biology
- Abstract
- Angiogenesis underlies development, physiology and pathogenesis of cancer, eye and cardiovascular diseases. Inhibiting aberrant angiogenesis using anti-angiogenic therapy (AAT) has been successful in the clinical treatment of cancer and eye diseases. However, resistance to AAT inevitably occurs and its molecular basis remains poorly understood. Here, we uncover molecular modifiers of the blood endothelial cell (EC) response to a widely used AAT bevacizumab by performing a pooled genetic screen using three-dimensional microcarrier-based cell culture and CRISPR-Cas9. Functional inhibition of the epigenetic reader BET family of proteins BRD2/3/4 shows unexpected mitigating effects on EC survival and/or proliferation upon VEGFA blockade. Moreover, transcriptomic and pathway analyses reveal an interaction between epigenetic regulation and anti-angiogenesis, which may affect chromosomal structure and activity in ECs via the cell cycle regulator CDC25B phosphatase. Collectively, our findings provide insight into epigenetic regulation of the EC response to VEGFA blockade and may facilitate development of quality biomarkers and strategies for overcoming resistance to AAT.
- Research Division(s)
- Epigenetics And Development
- PubMed ID
- 34267311
- Publisher's Version
- https://doi.org/10.1038/s42003-021-02397-3
- Open Access at Publisher's Site
https://doi.org/10.1038/s42003-021-02397-3- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2021-07-20 11:18:06
Last Modified: 2021-07-20 11:58:57